The Carlyle Group takes majority stake in HGH Systèmes Infrarouges

The Carlyle Group has announced the acquisition of a majority stake in HGH Systèmes Infrarouges through its Carlyle Europe Technology Partners III fund, as part of a structured control transaction. This move is part of a broader strategy to strengthen the fund's position in high-value-added electro-optical and infrared technologies. Beyond the transaction's structuring, the partnership aims to accelerate HGH's international growth by leveraging Carlyle's investment capabilities and industrial network. The goal is to support the company's expansion in the defense, security, and critical infrastructure markets, as well as in applications related to emerging asymmetric threats. To achieve this, Carlyle plans to support HGH's technological and commercial development, with increased investments in R&D and a focus on expanding the company's infrared surveillance and image analysis solutions. The completion of the transaction remains subject to customary regulatory conditions and the obtaining of necessary approvals. This acquisition is part of a larger strategy to build specialized technology platforms focused on advanced surveillance systems and optronic solutions.

The acquisition of HGH Systèmes Infrarouges is part of the growth strategy of The Carlyle Group, which already has several external growth operations under its belt, notably Adb Safegate in 2017.